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A Cisplatin-Loaded Immuno-Chemotherapeutic Nanohybrid 
Bearing Immune Checkpoint Inhibitors for Enhanced Cervical 
Cancer Therapy 
Na Wang, Zhigang Wang, Zoufeng Xu, Xianfeng Chen, and Guangyu Zhu*
Abstract: The efficacy of conventional chemotherapy is hindered by 
cancer cells’ escape from the immune system. Herein, we report a 
multifunctional nanohybrid system for effective immuno-
chemotherapy against cervical cancer. This nanohybrid contains both 
immune checkpoint inhibitor and cisplatin anticancer prodrug, 
showing improved cellular accumulation and increased binding of Pt 
to DNA and resulting in elevated apoptosis than using cisplatin alone 
when tested in cervical cancer cells. Intriguingly, the use of immune 
checkpoint inhibitors enables the inhibition of indoleamine-2,3-
dioxygenase and reverses immunosuppressive T cells to recognize 
cancer cells, leading to T cell proliferation and activation, cancer cell 
cycle arrest, and ultimately increased cancer cell death. The 
nanohybrid is also active in vivo against the growth of human cervical 
tumor. Overall, we provide a novel strategy using a multifunctional 
nanohybrid system to boost the antitumor activity of cisplatin, the gold 
standard chemotherapeutic treatment for cervical cancer. 
Immune response against cancer is developed by innate effector 
cells and particularly relies on T cells,[1] which are sensitive to the 
level of tryptophan.[2] In the presence of cancer cells, tryptophan 
is degraded to kynurenine by indoleamine-2,3-dioxygenase (IDO), 
an essential enzyme in the kynurenine pathway.[3] The tryptophan 
metabolites or inadequate tryptophan consequently lead to T cell 
anergy, tilting the immune system toward tumor support.[4] 
Recently, small molecules have emerged to address IDO 
inhibition and revive T cells for cancer immunotherapy.[5] The 
front-runner of IDO inhibitors, D-1-methyl-tryptophan (D-1MT), 
has entered clinical trials against multiple types of cancers,[6] but 
the detailed mechanism of this weak IDO inhibitor is still 
controversial.[7] More specific and potent IDO inhibitors are in the 
pipeline.[8] Although IDO inhibitors as well as other immune 
checkpoint inhibitors have launched inspired clinical successes 
for cancer immunotherapy, satisfactory tumor regression has 
been only achieved in some patients with advanced cancer, while 
other patients do not respond, indicating a large room to further 
improve.[9]  
Some common chemotherapies are potentiated by IDO 
inhibitors.[10] For example, cisplatin, a first-line chemotherapeutic 
in clinics,[11] can induce more significant tumor regressions than 
single-agent therapy when combined with IDO inhibitors.[10] 
Besides, with the addition of cisplatin, the T cell-mediated 
antitumor immunity is enhanced by indirectly producing additional 
proinflammatory signals.[10, 12] Thus, a combination of cisplatin 
with IDO inhibitors may strengthen the dual advantages and 
overcome the limitations of immunotherapy and chemotherapy. 
Delivery of cisplatin together with IDO inhibitors will take 
advantage of not only the potential synergism from the two 
warheads but also delivery vehicles to achieve enhanced 
anticancer efficacy; however, the development of such an 
effective anticancer complex is still a nascent area. 
Herein, we report an immuno-chemotherapeutic weapon for 
enhanced cervical cancer therapy. A nanohybrid ratiometrically 
co-loaded with IDO inhibitor and cisplatin prodrug was assembled, 
expected to be effective against cancer cells by killing them with 
cisplatin but simultaneously stimulating T cells to promote the 
apoptosis of cancer cells. This strategy of treating cervical cancer 
with immuno-chemotherapeutic nanomedicine to stimulate the 
function of T cells through IDO blocking might provide a new way 
of conquering cervical tumor especially that responds poorly to 
conventional chemotherapeutics.  
To assemble a nanohybrid co-loaded with IDO inhibitors and 
chemotherapeutics, a reliable nanoparticle system is required. 
Layered double hydroxide (LDH) nanoparticles were utilized in 
our study, as they are biocompatible and biodegradable, with low 
toxicity and high cancer-cell selectivity.[13] We choose 4-{[2-(4-
bromophenyl)hydrazinyl]sulfonyl}benzoic acid, a more potent IDO 
inhibitor (IDOi) than D-1MT, as the immune checkpoint 
inhibitor.[14] For chemotherapeutic regimen, a cisplatin prodrug 
c,c,t-[Pt(NH3)2Cl2(O2CCH2CH2COOH)2] (disuccinatocisplatin, 
DSCP) is utilized. In our design, the anionic property of both IDOi 
and the cisplatin prodrug ensures their efficient co-loading into the 
interlayer regions of LDH nanoparticles through anion exchange. 
More importantly, we take advantage of Pt(IV) prodrugs including 
lowered toxicity and efficient activation by intracellular 
reductants.[15] We expect that the nanohybrid enters cells through 
endocytotic pathways and the Pt(IV) prodrug is released from the 
nanohybrid and induces apoptosis in cancer cells; simultaneously, 
the IDOi discharges from the nanohybrid and boosts the T cell 
proliferation and immune response against cancer cells in a tumor 
microenvironment (Scheme 1). 
Mg/Al LDH nanoparticles were fabricated through our 
previously established method.[16] Various ratios of DSCP and 
IDOi were subsequently co-loaded into LDH nanoparticles by 
anion exchange, and the loaded nanohybrid was designated as 
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Pt(IV)-IDOi/LDH. Pt contents in the nanohybrid were measured 
by inductively coupled plasma-optical emission spectroscopy 
(ICP-OES), while the concentration of IDOi was determined by 
UV-vis spectroscopy. The molar ratios of the loaded Pt to IDOi in 
LDH were determined to be 10:1, 1:2, 1:10, 1:40, and 1:245. 
Pt(IV)/LDH and IDOi/LDH were assembled as controls (Table S1).  
Scheme 1. Strategic overview of a cisplatin-loaded nanohybrid for immuno-
chemotherapy. The nanohybrid Pt(IV)-IDOi/LDH enters cancer cells and 
releases Pt(IV) prodrug and IDOi. The former is reduced to cisplatin that binds 
to genomic DNA to induce cancer cell apoptosis; simultaneously, the latter 
blocks the pathway to produce kynurenine, leaving more tryptophan in the 
microenvironment for T cell proliferation and development. With the checkpoint 
inhibitor IDOi, proliferated T cells can distinguish cancer cell through the signal 
from antigen present cell (APC, such as dendritic cell), and enhance the 
chemotherapy. At last, the nanohybrid elevates cancer cell cycle arrest and 
apoptosis. Abbreviations are as follows: IDO, indoleamine-2,3-dioxygenase; 
TCR, T cell receptor; MHC, major histocompatibility complex; Trp, tryptophan; 
Kyn, kynurenine. 
The nanohybrid was characterized by transmission electron 
microscopy (TEM) and dynamic light scattering (DLS) 
measurement. The TEM images illustrate the typical hexagonal 
morphology of LDH, Pt(IV)/LDH, and IDOi/LDH (Figure S1). 
Apparently, for Pt(IV)-IDOi/LDH with different co-loading ratios 
(10:1, 1:2, 1:10, and 1:40), the nanohybrid remains the typical 
morphology of LDH. However, when the ratio of Pt(IV) to IDOi 
reaches 1:245, the nanohybrid aggregates and forms several 
clusters (Figure S1). Therefore, the Pt(IV)-IDOi/LDH with the 
loading ratio of 1:245 was excluded from further investigation. 
With the successful insertion of Pt(IV) and IDOi into LDH 
nanoparticles, the decrease of zeta potential and the increase of 
hydrodynamic size are noted (Table S2). The gradual decrease 
of zeta potential is ascribed to the increased loading amount of 
negatively charged DSCP and IDOi, neutralizing the positively 
charged LDH. The average hydrodynamic size of LDH is 73.8 ± 
2.1 nm, and the value steadily increases to 117.2 ± 5.1, 158.2 ± 
18.9, 176.9 ± 11.6, and 216.7 ± 30.8 nm for Pt(IV)-IDOi/LDH with 
Pt(IV):IDOi ratios of 10:1, 1:2, 1:10, and 1:40, respectively (Table 
S2).  
The cytotoxicities of the nanohybrid against HeLa and A549 
cancer cells were determined. HCvEpC human cervical epithelial 
cells and WI-38 human lung fibroblast cells were included as 
comparisons (Table 1). HeLa and A549 cells were chosen 
because the expression levels of IDO are higher in those cells 
especially the former than others including MCF-7, A2780, and 
A549cisR (Figure S2). LDH nanoparticles themselves show 
negligible cytotoxicity with IC50 > 400 μg/mL in the two cell lines. 
Cisplatin shows typical IC50 values in the low micromolar range. 
Pt(IV)/LDH has a higher cytotoxicity than cisplatin, indicating the 
efficiency of the delivery system. The IC50 values of Pt(IV)-
IDOi/LDH with a loading ratio of 1:2, 1:10, and 1:40 in HeLa cells 
are 1.5 ± 0.3, 0.7 ± 0.5, and 0.3 ± 0.1 μM, respectively. Clearly, 
Pt(IV)-IDOi/LDH exhibits more significant cytotoxicity in the 
cervical cancer cells. Moreover, the increased amount of IDOi 
enhances the cytotoxicity of the nanohybrid, which is likely from 
the inhibition of tryptophan degradation.[17] A similar trend is 
observed in A549 cells, and the Pt(IV)-IDOi(1:40)/LDH shows the 
highest cytotoxicity in the sub-micromolar range. In contrast, the 
nanohybrid is not significantly active in IDO-expressing HCvEpC 
and WI-38 cells (Figure S2). The cytotoxicity of Pt(IV)-
IDOi(1:40)/LDH toward HCvEpC cells is 26-time lower than that 
in HeLa cells, while the cytotoxicity in WI-38 cells shows 16-time 
lower than that in A549 cells, suggesting the high cancer-cell 
selectivity of the nanohybrid. Since Pt(IV)-IDOi(1:40)/LDH shows 
the highest cytotoxicity in the IDO-expressing HeLa cells, we 
utilize this sample and the cervical cancer cells for the following 
biological assays.  
Cancer cells can be disguised by kynurenine and are able to 
evade from the immune system via IDO-mediated tryptophan 
pathway.[18] Hence, the capacity of Pt(IV)-IDOi(1:40)/LDH to block 
kynurenine production in HeLa cells was examined. An Ehrlich’s 
reagent (2% p-dimethylaminobenzaldehyde) was utilized to react 
with kynurenine, and the level of this tryptophan metabolite was 
quantified.[19] The half maximum effect concentration (EC50) 
shown in Table S3 and the level of kynurenine in Figure S5 
represent the inhibitory efficacy of kynurenine production in HeLa 
cells. D-1MT has an EC50 value of >1 mM, confirming its weak 
inhibitory effect. The IDOi we use shows a stronger inhibitory 
effect than D-1MT against the catalytic activity of IDO in HeLa 
cells with an EC50 value of 163 ± 24 μM. In contrast, IDOi/LDH is 
very effective in blocking the kynurenine production, and its EC50 
value is 4.0 ± 0.3 μM, indicating the efficient delivery of IDOi into 
the cells. Intriguingly, Pt(IV)-IDOi(1:40)/LDH shows the highest 
activity with an EC50 value of 1.9 ± 0.2 μM against kynurenine 
Table 1. Cytotoxicity of different complexes in HeLa, A549, and WI-38 cells. 
The cells were incubated with complexes for 72 h, and cell viability was 
tested by MTT assay. 
  
Complex 
IC50/μM[a]   
HeLa A549 HCvEpC WI-38  
LDH[b]  > 400 > 400 N.D. N.D.  
Cisplatin 5.1 ± 2.0 2.6 ± 0.6 1.4 ± 0.4 3.3 ± 1.4  
Pt(IV)/LDH 3.5 ± 1.0 N.D.[c] 8.9 ± 2.3 17.2 ± 6.8  
IDOi/LDH 9.1 ± 4.3 N.D. N.D. N.D.  
Pt(IV)-IDOi(10:1)/LDH 4.7 ± 2.0 N.D. N.D. N.D.  
Pt(IV)-IDOi(1:2)/LDH 1.5 ± 1.0 5.0 ± 0.6 N.D. N.D.  
Pt(IV)-IDOi(1:10)/LDH 0.7 ± 0.5 1.5 ± 0.3 N.D. N.D.  
Pt(IV)-IDOi(1:40)/LDH 0.3 ± 0.1 0.7 ± 0.2 7.9 ± 2.9 11.1 ± 2.7  
D-1MT 7900 ± 261 > 1000 N.D. N.D.  
[a] For complexes containing Pt, the concentration equivalent to Pt 
concentration. [b] The unit of LDH is presented as μg/mL. [c] N.D. Not 
determined. 
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production, showing the effectiveness of the nanohybrid to inhibit 
IDO. 
With the reduction of kynurenine production, T cells can 
proliferate to boost anti-tumor immune responses.[20] Mixed 
leukocyte reactions (MLRs) is applied for measuring the cellular 
immune response in vitro. Human peripheral blood mononuclear 
cells (PBMCs) were employed to mimic the immune 
microenvironment in the body because it consists of lymphocytes 
and monocytes.[21] A double-staining flow cytometric assay was 
applied for the detection of T cell proliferation. In the experiment, 
PBMCs from unrelated healthy donors were stimulated by 
phytohemagglutinin-M (PHA-M), a lectin, for T cell activation. The 
cells were subsequently stained with carboxyfluorescein 
succinimidyl ester (CFSE), a fluorescent cell staining dye without 
adverse effect to cell health, and co-cultured with adherent HeLa 
cells. The HeLa/MLRs were treated with the complexes, and 
PBMCs were harvested and stained with a FITC-conjugated anti-
CD3 antibody. Here, CD3 acts as a marker representing the 
development of T cells, which is also required for T cell 
activation.[22] After treatment, CFSE-labeled and CD3+ dual-
positive T cells were analyzed for the changes of proliferating T 
cells. The depleting of IDO enzyme induced by our nanohybrid 
may lead to T cell proliferation in this HeLa/MLRs system.  
When HeLa cells are mixed with PBMCs without any 
treatment, the percentage of T cell proliferation is as low as 5.6% 
(Figure 1A). In the group containing a mixture of D-1MT and 
cisplatin, 29.8% of T cells proliferate, and the value increases to 
35.3% for a mixture of IDOi and cisplatin, indicating the 
effectiveness of IDOi in stimulating T cell activity (Figure 1B and 
1C). Remarkably, HeLa/MLRs treated with Pt(IV)-IDOi(1:40)/LDH 
have 41.9% of T cell proliferation, which is higher than the results 
from the control or the co-treatment without nanocarrier, showing 
that our nanohybrid can effectively stimulate the proliferation of T 
cells (Figure 1D). The subsequent generation of divided T cells 
was then analyzed based on the increasing dilution of CFSE. 
Each additional peak, shown in the pink color in Figure 1, 
indicates one subsequent generation of T cells. After 6 days, the 
HeLa/MLRs incubated with Pt(IV)-IDOi(1:40)/LDH apparently 
show more T cell generations than all the other groups, further 
confirming the proliferation of T cells. Together with the 
cytotoxicity results above, it is obvious that our nanohybrid is an 
effective immuno-chemotherapeutic agent that can 
simultaneously kill cervical cancer cells and stimulate T cell 
proliferation.  
The above-mentioned HeLa/MLRs system only corroborates 
the proliferation of T cells, but the subsequent effect on cancer 
cells is still unknown. To know this, cell cycle distribution of HeLa 
cells in the presence of PBMCs after treatment with Pt(IV)-
IDOi/LDH was measured. HeLa cells without treatment display a 
normal profile of cell cycle distribution (Figure 2A). The cells 
treated with Pt(IV)-IDOi/LDH without the presence of PBMCs are 
arrested at the S phase (43.2%), and we attribute this cell cycle 
arrest to the efficient delivery of cisplatin prodrug into HeLa cells 
to arrest the cell cycle. In contrast, our nanohybrid arrests the 
HeLa cells at the S phase more strongly in the presence of 
PBMCs. Under this condition, 67.6% of the cells stay at the S 
phase, indicating the role of activated T cells in arresting the cell 
cycle of HeLa cells, possibly through the blockage of Cytotoxic T-
Lymphocyte Antigen 4 (CTLA-4) ligands.[23]  
Figure 1. Measurement of T cell proliferation in HeLa/MLRs system after 
cultured with/without different complexes for 6 days. A) medium only, B) 1.6 μM 
D-1MT and 0.04 μM cisplatin, C) 1.6 μM IDOi and 0.04 μM cisplatin, and D) 
Pt(IV)-IDOi(1:40)/LDH (equivalent to 1.6 μM IDOi and 0.04 μM Pt) were added 
in the HeLa/MLRs co-culture system. After 6 days, the CFSE-labeled CD3+ T 
cells were quantified using a flow cytometer. Black line – population signal of 
dual-positive stained cells detected from flow cytometry; green line – fitting 
curves of black line for T cell proliferation analysis. Each additional peak (pink) 
indicates one subsequent generation of T cells analysed by software. The 
details are given in the Supplementary Information.  
The apoptotic level of HeLa cells after T cell proliferation and 
activation in the HeLa/MLRs co-culture system was further 
examined. HeLa or HeLa/MLRs cells were exposed to Pt(IV)-
IDOi/LDH, and HeLa cells were subsequently harvested and 
stained with Annexin V-FITC/7-AAD for flow cytometric analysis. 
For untreated group, the fractions of early apoptotic and late 
apoptotic cells are 2.6% and 14.1%, respectively (Figure 2B). In 
Pt(IV)-IDOi/LDH-treated group, the values significantly increase 
to 39.7% and 23.6% for early apoptosis and late apoptosis, 
respectively, indicating that our nanohybrid is able to effectively 
induce apoptosis in HeLa cells due to the presence of the 
chemotherapeutic warhead (Figure 2C). Particularly, when the 
cells were treated with the same concentration of the nanohybrid 
in the presence of PBMCs, significant escalation of late apoptosis 
(53.9%) was observed (Figure 2D). Apoptotic induction ability of 
the nanohybrid was further illustrated by labeling the fragmented 
DNA with the use of a TUNEL assay. Apoptosis occurred in HeLa 
cells treated with the nanohybrid in and without the presence of 
PBMCs (Figure S6). Apparently, the presence of PBMCs results 
in a higher level of apoptosis (50.2%) compared with the 
nanohybrid alone (33.9%) (Figure S7). Therefore, the presence of 
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activated T cells accelerates the apoptosis of the cervical cancer 
cells. Collectively, the data suggest that T cell activation is able to 
arrest the cell cycle and promote apoptosis in cancer cells when 
treated with our nanohybrid.  
Figure 2. Flow cytometry analysis of A) cell cycle arrest of untreated cell and in 
complex with/ without PBMCs. Flow cytometry analysis of apoptosis with B) 
Annexin V/7-AAD staining of HeLa as control, C) Pt(IV)-IDOi(1:40)/LDH and D) 
Pt(IV)-IDOi(1:40)/LDH with PBMCs, after 3 days of culture. [Pt] = 5 μM. *** p < 
0.001, Student’s t-Test. Mean ± SD. 
The antitumor activity of our nanohybrid in vivo was further 
demonstrated. Because BSA-coated LDH nanoparticles have 
shown great biocompatibility in vivo,[24] we prepared BSA-coated 
Pt(IV)-IDOi(1:40)/LDH. The shape, size, and zeta potential of the 
BSA-coated nanohybrid do not change significantly after 24 h 
incubation in blood plasma (Figures S11, S12, and Tables S4, S5). 
The BSA-coated nanohybrid was then used for an anticancer 
efficacy test in nude mice bearing HeLa xenograft. To verify the 
immuno-chemotherapeutic function of our nanohybrid, PHA-M-
stimulated PBMCs were intravenously (i.v.) injected into two 
groups of mice to engraft human immune system in the 
immunodeficient mice after the HeLa tumor nodules were 
palpable.[25] Twenty four hours after PBMCs injection, BSA-
coated Pt(IV)-IDOi(1:40)/LDH or PBS were injected (i.v.) for total 
4 times at one day interval (Figures 3 and S13). After 14 days, 
BSA-coated Pt(IV)-IDOi(1:40)/LDH exhibits significantly stronger 
tumor inhibition than the other two groups (p < 0.001). Notably, 
the size of tumors in the group of PBMCs with the nanohybrid 
(291.7 ± 125.6 mm3) is significantly smaller than the one in the 
group treated with the nanohybrid only (662.2 ± 168.5 mm3) (p < 
0.05), suggesting the effectiveness of our immuno-
chemotherapeutic warhead in the presence of PBMCs. The body 
weight of each group increases gradually, indicating the safety of 
our nanohybrid (Figure S14). The level of free kynurenine and 
tryptophan in tumors was quantified by HPLC. Both the level of 
kynurenine and the ratio of kynurenine to tryptophan significantly 
decrease in the nanohybrid-treated groups compared with the 
untreated ones (Figure S15), revealing the inhibition of IDO by the 
nanohybrid in vivo. These results further confirm the efficacy of 
the nanohybrid in immune-chemotherapy in vivo. 
In summary, we report the first example of a nanohybrid 
system bearing both IDOi and cisplatin as an immune-
chemotherapeutic weapon to significantly boost the antitumor 
activity of cisplatin against cervical cancer. The nanohybrid 
containing chemotherapeutic regiments displays dramatically 
increased capability to kill HeLa cells without the presence of 
PBMCs, with a 17-fold increase in cytotoxicity compared with 
cisplatin alone. Remarkably, the presence of PBMCs in the 
system significantly boosts the antitumor activity of the 
nanohybrid, evidenced by the activation of T cells, the cell cycle 
arrest of HeLa cells induced by T cells, and the significantly 
increased fraction of late apoptotic HeLa cells resulted from the T 
cell activation. Compared with a small-molecule conjugate of D-
1MT and cisplatin,[26] our nanohybrid apparently has many 
advantages, such as capability of tuning the ratio of IDOi and 
cisplatin to maximize the effectiveness of the system, limited 
premature reduction of cisplatin prodrug protected by 
nanoparticles,[27] cancer cell specificity, and potential passive 
tumor targeting due to the enhanced permeability and retention 
(EPR) effect. Our nanohybrid is, therefore, a very powerful 
antitumor complex utilizing a combinatorial strategy of both 
chemotherapy and immunotherapy, conveying a drug delivery 
system based on nanoparticles to overcome the current issues of 
efficient cancer therapy. 
Figure 3. The growth of HeLa tumors in xenograft model with various treatment 
groups indicated. PBMCs (5 x 106 cells/mouse) were injected intravenously on 
Day 0. BSA-coated Pt(IV)-IDOi(1:40)/LDH ([Pt] = 0.5 mg/kg) was injected for 
total 4 times of injection. The tumor volume of each group was measured every 
two days for 14 days of duration. * p < 0.05, *** p < 0.001, Student’s t-Test. 
Mean ± SD, n = 5. 
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Experimental Details 
Materials and general instruments 
All the related chemicals were acquired from commercial resources, except the IDO inhibitor was prepared following the 
reported protocols[1] and characterized by 1H NMR and 13C NMR. Trichloroacetic acid (TCA), p-
Dimethylaminobenzaldehyde (Ehrlich’s reagent), ethanol, D-1-methyl-tryptophan (D-1MT), L-tryptophan, L-kynurenine, 
glacial acetic acid, ethylenediaminetetraacetic acid (EDTA) and Triton X-100 were obtained from Sigma-Aldrich Pty Ltd. 
Dulbecco's modified eagle medium (DMEM), Roswell Park Memorial Institute 1640 (RPMI 1640) medium, minimum 
essential medium (MEM), trypsin, phosphate buffered saline (PBS), fetal bovine serum (FBS), non-essential amino acids 
(NEAA), sodium pyruvate, 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT), recombinant human 
interferon-γ (hIFN-γ), propidium iodide (PI), 7-amino actinomycin D (7-AAD), annexin V-FITC, phytohemagglutinin-M 
(PHA-M), and CellTrace Far Red cell proliferation kit (carboxyfluorescein succinimidyl ester, CFSE) were obtained from 
Life Technologies. Bovine Serum Albumin (BSA) lyophilized powder was purchased from Acros Organics. IDO primary 
antibody (Cell Signaling Technology) and secondary antibody (Life Technologies) were purchased for western blotting. 
Flow cytometry experiments were performed at CytoFLEX S Flow Cytometer (Beckman). Peripheral blood mononuclear 
cells (PBMCs, Lonza) from unrelated healthy donators and FITC-conjugated anti-CD3 antibody (Abcam, ab34275) were 
purchased for flow cytometry. DeadEndTM Fluorometric TUNEL System (G3250) was obtained from Promega 
Corporation, USA. 
 
Synthesis of Pt(IV)/LDH, IDOi/LDH, Pt(IV)-IDOi/LDH 
Cisplatin prodrug c,c,t-[Pt(NH3)2Cl2(O2CCH2CH2COOH)2] (DSCP), IDO inhibitor 4-{[2-(4-
Bromophenyl)hydrazinyl]sulfonyl}benzoic acid (IDOi) and layered double hydroxides (LDH) were prepared following the 
reported literatures[2] and our previous work,[3] respectively. Pt(IV)/LDH was synthesized as the previous reports[4]. Briefly, 
1.5 mL DSCP (5 mM, pH 8.0) and LDH were stirred together overnight, and the synthesized suspension was washed 
twice with Milli-Q water for further study. For the synthesis of IDOi/LDH, IDOi (20 mM, 1.325mL, pH 8.0) was added to a 
suspension of LDH nanoparticles (4.0 mg/mL, 1.0 mL) and stirred overnight in dark. The complex was then washed 
twice with 12,000 × g centrifugation for 10 min and resuspended in Milli-Q water. Pt(IV)-IDOi/LDH with different ratios of 
Pt(IV) and IDOi were synthesized through a similar process. 500 μL DSCP (5 mM) and various amount of IDOi were 
added in LDH nanoparticles suspension before stirred overnight. All the prepared samples were stored at 4C in dark.  
 
Characterization of nanoparticles 
The Pt content in the nanoparticles was determined by Inductively Coupled Plasma Optical Emission Spectrometry (ICP-
OES, PerkinElmer, Optima 8000). UV-vis spectroscopy (Shimadzu, UV-1700 PharmaSpec, UV-vis Spectrophotometer) 
was applied to quantify the amount of IDOi in the nanoparticles. Transmission Electron Microscopy (TEM, Philips Technai 
12) was employed for morphology analysis. The size distribution and zeta potential were measured by dynamic light 
scattering (DLS) on Malvem Zetasizer Nano ZS. 
 
Pt and IDOi content in nanoparticles 
Pt release level in each sample (100μL) was digested by 400 μL concentrated nitric acid overnight, then the mixture was 
diluted with 500 μL DI water before ICP-OES measurement. The nanoparticles (100 μL) were pretreated with 0.1 N HCl 
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(900 μL) overnight to break down LDH and to release free IDOi before UV-vis spectroscopy measurements. The 
absorbance peak of IDOi at 230 nm was employed to calculate the concentration of IDOi in the digested solution. 
 
Cell lines and cell culture conditions 
HeLa, MCF-7, A549 and A549cisR cells were maintained in DMEM with 10% FBS and 50 U/mL penicillin and 
streptomycin. A2780 cells were maintained in RPMI 1640 with 10% FBS, 2 mM L-glutamine and 50 U/mL penicillin and 
streptomycin. WI-38 cells (human lung fibroblast) were maintained in MEM with 10% FBS, 1% L-glutamine, 1% NEAA 
and 1% sodium pyruvate. Human cervical epithelial cells (HCvEpC) were obtained from Cell Applications, Inc., and 
maintained in Epithelial Cell Growth Medium (Cell Applications, Inc., USA). A kind of special medium (10% dextrose, 
40% RPMI and 50% FBS) was applied to thaw the PBMCs and the cells were consequently cultured in RPMI complete 
culture medium (20% FBS). To mimic in vivo circumstances, the processes to change the medium in PBMCs culture 
flask were modified as described: half of the culture medium was taken out from the flask, then the supernatant was 
discarded after centrifugation, the cell pellet was resuspended in fresh medium and mixed with the original half volume 
of PBMCs in the flask. With the purpose of keeping some growth factors or cytokines inside, the procedure will lose a 
few PBMCs after medium changed undoubtedly. All the cells were grown in a humidified incubator at 37˚C with 5% 
carbon dioxide. 
 
Western blotting 
MCF-7, HeLa, A2780, A549, A549cisR, WI-38, MRC-5, and HCvEpC cells (1 × 106 cells) were incubated with or without 
hIFN-γ (50 ng/mL) in 10 cm petri dish for 3 days at 37˚C. Cells were washed with cold PBS for twice. Cells were scraped 
and lysed, then quantified and mixed with loading buffer. The whole cell lysates were applied in sodium dodecylsulphate 
polyacrylamide gel electrophoresis (SDS-PAGE, 10% resolving gel and 15% stacking gel) at 70 V for about 150 min, 
and transferred to polyvinylidene difluoride membrane (PVDF) with 700 mA for 60 min. Membranes were subsequently 
blocked with 5% (w/v) nonfat milk powder in TBST (Tris buffer saline with 0.1% tween-20) for 1 h at room temperature 
and incubated with the IDO primary antibody (Cell signaling Technology) overnight. The membranes washed with 4% 
milk Tris buffer saline for 3 to 5 times. After incubation of horseradish peroxidase conjugated secondary antibody 
(Thermo Scientific) for 1h, the membrane was washed with TBST for 3 to 5 times, followed by ECL reagent (Thermo 
Scientific) and imaged with Bio-Red ChemiDocTM Touch Imaging System. 
 
Cell viability tests 
MTT assay was employed to measure the cell viability. HeLa, A549, WI-38 cells (3 × 103 cells/well) and HCvEpC (6.5 × 
103 cells/well) were seeded in 96-well plates and incubated overnight. The fresh medium containing various 
concentrations of complexes was subsequently added when the cells reach about 30% confluency in each well. 72 h 
later, the medium in each well was replaced by the serum-free medium containing 1 mg/mL MTT. After 1 h of incubation, 
200 μL DMSO was added after the removal of medium to dissolve the formazan in each well. The absorption of 550 nm 
and 700 nm was measured in a microplate reader. The viability of PBMCs (100 μL) from different treatment conditions 
was determined by using the MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfonyl)-2H-
tetrazolium) reagent (Promega Corporation, USA). 
 
Cellular accumulation of platinum in HeLa cells 
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HeLa cells were seeded in 10 cm petri dishes and incubated until the cell confluency reached 80%. The medium was 
changed to fresh medium containing cisplatin, cisplatin with IDOi (1:40), Pt(IV)/LDH and Pt(IV)-IDOi(1:40)/LDH at the 
concentration of 5 and 10 μM Pt. After 8 h, cells were collected and washed with ice-cold PBS for 3 times. Cell pellet 
was resuspended in 1 mL PBS. The cells were then digested by 30% conc. nitric acid overnight at 65˚C, and the Pt 
content was measured by ICP-OES. The platinum level in cells was expressed as ng Pt per 106 cells. 
 
Pt level in Genomic DNA 
HeLa cells were seeded in 10 cm petri dishes and incubated until the cell confluency reached 80%. The medium was 
changed to fresh medium containing cisplatin, cisplatin with IDOi (1:40), Pt(IV)/LDH and Pt(IV)-IDOi(1:40)/LDH at the 
concentration of 5 and 10 μM Pt. After 8 h of incubation, cells were harvested, counted, and washed with ice-cold PBS 
for 3 times. The cell pellet was resuspended in 2 mL of a lysing buffer (100 mM Tris-HCl, pH 8.5, 5 mM EDTA, 0.2% 
SDS, 200 mM NaCl, 100 μg/mL proteinase K) and incubated overnight at 55˚C. The samples were extracted twice with 
2 mL of phenol/chloroform/isoamyl alcohol (25:24:1) (vortex and centrifugation at 4,500 rpm, 5 min). The supernatant 
was transferred to a new tube, and followed by two extractions with chloroform. Genomic DNA was precipitated with 0.7 
× sample volume of isopropanol, then washed with 0.7 × sample volume of ice-cold ethanol (70%) twice, centrifuged at 
15,000 rpm for 25 min. The DNA pellet was dissolved in 10 mM Tris/HCl (pH 8.0) buffer (10 mM tris, 1 mM EDTA, 50 
μg/mL RNase). The DNA concentration was quantitated by UV-vis spectroscopy. The amount of platinum on the DNA 
was determined by ICP-OES. The concentration of platinum was expressed as ng of platinum per 106 cells. 
 
Cell-based kynurenine assay 
HeLa cells were seeded in 48-well plates at a density of 3×104 cells/well. Then all the medium was removed on the next 
day. The hIFN-γ (25 ng/mL as final concentration) and various concentrations of complexes were added in a total volume 
of 200 μL of culture medium containing 100 μM of L-tryptophan. After 48 h of incubation, 140 μL supernatant in each 
well was transported into the 96-well plates and mixed with 15 μL of 30% TCA. The mixture was incubated for 30 min at 
50˚C. The microplates were then centrifuged for 10 min at 3,000  g to remove the sediments. 100 μL of the supernatant 
was mixed with 100 μL of 2 % (w/v) p-dimethylaminobenzaldehyde in acetic acid and measured at 480 nm in a microplate 
reader. The concentration of kynurenine in each sample was quantified from a kynurenine standard curve.  
 
T cell proliferation in HeLa/MLRs 
HeLa cells were seeded with a density of 1×103 cells/well in 6-well plates. Twenty-four hours after the HeLa cells 
cultivation, the medium in each well was replaced with 2 mL fresh complete DMEM containing various concentrations of 
complexes, 50 ng/ml IFN-γ and 0.1 mM L-tryptophan. The HeLa cells were exposed to different complexes for 2 d with 
Pt concentration is 0.04 μM. PBMCs (2 × 105 cells/well) stained with CellTraceTM Far Red Cell Proliferation Kit (CFSE) 
were subsequently inserted after PHA-M stimulation. After 6 days of co-culture, the PBMCs in each well were collected 
after centrifugation, the cell pellets were resuspended in PBS and labeled with FITC-conjugated anti-CD3 antibody. With 
cell staining finished, all the samples were collected and analyzed by flow cytometry. T cell proliferation analysis was 
implemented on CytoFLEX S flow cytometer (Beckman Coulter, USA). All the samples were tested with the excitation 
light of 630 nm and detected emission at 661 nm for CellTrace Far Red (CFSE) stained PBMCs, the excitation and 
emission wavelengths at 495 nm/519 nm were detected simultaneously for cells bound with FITC-conjugated anti-CD3. 
Signals from 10,000 events were collected for each sample. Based on the flow cytometric data, the T cell proliferation 
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in each sample was analyzed by FlowJo software. The dual-staining positive cells were taken as valid data in each 
sample. 
 
Flow cytometry protocol of cell gating: for the test of T cell proliferation in each sample, PBMCs were first stained with 
CFSE and labeled with FITC-conjugated anti-CD3 antibody six days later as described above. Then the PBMCs cells 
were analyzed by flow cytometer. For the analysis of data, FlowJo software was used. To determine the gate of 
proliferation T cells, three additional groups were included: a) the PBMCs without staining CFSE and FITC-conjugated 
anti-CD3 antibody; b) CFSE stained PBMCs, and c) FITC-conjugated anti-CD3 antibody labeled PBMCs. FL3 channel 
was set as the x-axis, FL1 channel was set as the y-axis. For CFSE+ cells, the gate was adjusted that FITC- but CFSE+ 
cells were displayed in the lower right quadrant. Similar gating way in CD3+ cells, gates were placed in such a way that 
FITC+ but CFSE- cells were displayed in the upper left quadrant, leaving the double-stained positive cells in the upper 
right quadrant, and the double-unstained cells in the lower left quadrant. Gates were kept for all samples. Only the upper 
right quadrant (FITC+, CFSE+) of each sample was selected as T cells and applied for T cell proliferation analysis. The 
proliferation of T cells was analyzed with FlowJo’s Proliferation Tool. FL3 channel was set as the x-axis, and the y-axis 
was Histogram. FlowJo modeled the division by looking for peaks with diminishing fluorescence with a ratio of 0.5 per 
generation. 
 
Cell cycle analysis for HeLa cells 
HeLa cells were cultured in 6-well plates with a density of 3 × 103 cells/well. 1 × 105 PBMCs were added into the HeLa 
cells with or without compounds ([Pt] = 5 μM). After 6 days of incubation, suspended PBMCs were removed and the 
HeLa cells were washed twice with PBS for cell cycle analysis. HeLa cells were then harvested and washed twice with 
PBS with centrifugation, 1,500 rpm/5 min. The cell pellets were resuspended in 0.5 mL PBS and fixed in 5 mL ethanol 
(70%) at 4˚C overnight. Then the fixed cells were washed after centrifugation, and resuspended in 1 mL PI solution (0.1% 
Triton X-100, 200 μg/mL RNase A, 20 μg/mL propidium iodide, pH 7.4). The cells were incubated at 37C for 30 min in 
dark. Cell cycle distribution was analyzed by a BD flow cytometer with excitation at 488 nm and emission at 632 nm. 
The data were analyzed by a FlowJo 7.6.1 software. 
 
Apoptosis analysis in HeLa cells using flow cytometry 
HeLa cells were seeded in 6-well plates at a density of 1 × 104 cells per well and incubated for 24 h. Pt(IV)-IDOi(1:40)/LDH 
([Pt] = 5 μM) were added with/without PHA-M activated PBMCs (3 × 105 cells/well). After 72 h of incubation, HeLa cells 
were harvested for apoptosis analysis. The cells were subsequently washed with cold PBS and annexin binding buffer, 
and the cell density was determined and adjusted to 1 × 106 cells per mL. Annexin V conjugated FITC and 7-AAD solution 
were added to 100 μL cells suspension. The cells were stained at RT for 15 min, then 400 μL annexin binding buffer 
was added and mixed gently. The as-prepared samples were kept on ice and analyzed by flow cytometer with excitation 
at 488 nm and emission at 532 nm and 650 nm for FITC and 7-AAD, respectively. 
 
Apoptosis analysis in HeLa cells using TUNEL 
HeLa cells (1 x 104) were seeded on slides and incubated for 24h before Pt(IV)-IDOi(1:40)/LDH ([Pt] = 5 μM) were added 
with/without PHA-M activated PBMCs (3 × 105). After 3 days of incubation, HeLa cells on the slides were fixed in 4% 
formaldehyde in PBS for 25 min at 4˚C, and washed twice in PBS. Sides were immersed in 0.2% Triton X-100 in PBS 
for 5 min for permeabilizing cells. Then cells equilibrated with 100 μL Equilibration Buffer at room temperature for 5-10 
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min, and labeled with 50 μL TdT reaction mix (45 μL Equilibration Buffer, 5 μL Nucleotide Mix and 1 μL rTdT Enzyme) 
at 37˚C for 60 min in a humidified chamber. Slides were protected from light since this step forward. Stop label reaction 
by immersing slides in 2 X SSC buffer, slides were washed three times with PBS to remove unincorporated fluorescein-
12-dUTP. To visualize all nuclei, freshly prepared PI working solution (1 μg/mL propidium iodide, in PBS) was applied 
to counterstain all samples. Samples were immediately analyzed under a motorized fluorescence microscope (Nikon 
Eclipse 90i). Apoptotic cells with green fluorescence were detected at 520 nm, and the nuclei with red fluorescence were 
viewed at 620 nm. ImageJ software was used for quantification. For the TUNEL result, the apoptotic index was 
expressed as the percentage of TUNEL-positive cells out of the total number of cells counted. 
 
Pt accumulation in HeLa, PBMCs, T cells and medium for delivery efficiency test 
HeLa cells (1 x 104) were seeded in 6-well plates and incubated for 24h following the addition of Pt(IV)-IDOi(1:40)/LDH 
([Pt] = 5 μM) with/without PHA-M activated PBMCs (3 × 105). After 72 h of incubation, PBMCs in each well were harvested 
and washed three times with ice-cold PBS, and resuspended in 1 mL PBS. The Pt accumulation in T cells was tested 
after sorting: the incubated PBMCs in HeLa/MLRs were washed three times with PBS, and sorted with SH800 Cell Sorter 
(Sony Biotechnology) after labeled with a FITC-conjugated anti-CD3 antibody. The PBMCs and sorted T cells were then 
digested by 30% conc. nitric acid overnight at 65˚C, and the Pt content was measured by ICP-MS (PerkinElmer Nexion 
2000). The platinum level in cells was expressed as ng Pt per 106 cells. The delivery efficiency test was carried in three 
different conditions: a) HeLa + Pt(IV)-IDOi(1:40)/LDH ([Pt] = 5 μM); b) HeLa + Pt(IV)-IDOi(1:40)/LDH ([Pt] = 5 μM) + 
PBMCs; and c) Pt(IV)-IDOi(1:40)/LDH ([Pt] = 5 μM) + PBMCs. After 72 h of incubation, HeLa cells, supernatant in each 
well, and PBMCs were harvested for the ICP-MS test as above. 
 
Preparation of BSA-coated nanohybrid 
Albumin-coated nanoparticles were synthesized for the in vivo experiment[5]. In brief, 5 mL suspension of as-prepared 
Pt(IV)-IDOi(1:40)/LDH was added into 5 mL BSA stock solution (10 mg/mL) dropwise with the albumin/ LDH mass ratio 
of 5 : 2 under vigorous stirring. The reaction was stirred for 30 min and protected from light. After the reaction, the BSA-
coated nanohybrid was washed 3 times with PBS and re-suspended in PBS for in vivo experiment. 
 
Characterization of nanohybrid and BSA-coated nanohybrid in blood plasma  
Whole blood was collected from healthy BALB/c nude mice into the EDTA-treated microtube. Then the cells were 
removed from plasma by centrifugation for 15 min at 2,000 x g, 4˚C. To check the characterization of nanoparticles in 
blood plasma, centrifuged nanoparticles or BSA-coated nanoparticles (12,000 x g, 10 min) were dispersed in 300 μL 
mice blood plasma. After 5 s of vortex, 100 μL of blood plasma and nanohybrid mixture were taken out and washed 
twice with PBS (12,000 rpm, 10 min) for characterization at 0 h. The rest mixture was maintained in 37 ˚C for 24 h. TEM, 
size distribution and zeta potential of the samples were taken for the characterization 
 
In vivo anti-tumor efficacy in subcutaneous HeLa xenograft mouse model 
To evaluate the immune-chemotherapeutic nanohybrid, an anti-tumor efficacy model was established on BALB/c 
background nude mice. The HeLa cervical cancer cells (5 × 105 cell / 0.1 mL / mouse) were subcutaneously implanted 
in the right axillary fossa of BALB/c nude mice (6-week-old, 18 - 23 g body weight) to establish the xenograft mouse 
S8 
 
model. Tumor nodules were allowed to grow 7 days to achieve a diameter of 5 - 8 mm before treatment initiation. All the 
mice were numbered with ear tags. The treatment phase included intravenously injection of PHA-M-activated normal 
PBMCs (approximately 5 x 106 cell / 0.1 mL / mouse), followed on intravenously injection of BSA-coated Pt(IV)-
IDOi(1:40)/LDH ([Pt] = 0.5 mg/kg) and PBS as a negative control (Figure S12). The BSA-coated nanohybrid was injected 
every two days for total four times of injection. Since HeLa cells grow aggressively in nude mice, the experiment is 
terminated on Day 14. The tumor dimension and body weight were measured every two days for 14 days of duration. 
Tumor length and width were measured with calipers, and the tumor volume was calculated using the following equation: 
TV=(a)(b2)π/6, where a is the longest dimension and b is the largest dimension orthogonal to a. Statistical analysis was 
performed using Student’s t-Test at the end point. 
 
Determination of tryptophan and kynurenine level in tumor by high-pressure liquid chromatography (HPLC) 
All the mice in each group were sacrificed after experiment terminated, tumors were harvested and frozen at -80 ˚C after 
washed in phosphate-buffered saline. The total free tryptophan and kynurenine in tumors were quantified by HPLC[6]. 
The tumors were homogenized with ice-cold 0.16 M perchloric acid containing 0.1% EDTA and 0.1% ascorbic acid for 
5 min and centrifuged at 20,000 x g for 20 min, and the supernatant was filtered for HPLC. The chromatography was 
performed in a Shimadzu LC-20AT liquid chromatograph with a 250- by 4.6-mm (inner diameter) C18 reverse-phase 
column (Phenomenex, Gemini 5 μ C18 110A). In tryptophan measurement, the column was eluted at a flow rate of 1.0 
ml/min with 0.015 M sodium acetate (pH 4.5) containing 15% methanol for analysis of tumor samples. For kynurenine 
determination, the column was eluted with acetonitrile at a 1:47 dilution in 0.1 M acetic acid-0.1 M ammonium acetate 
(pH 4.65). The absorbance of the column effluent was monitored at 280 and 365 nm for tryptophan and kynurenine, 
respectively. The peaks of tryptophan or kynurenine were identified by comparison with the retention time of standard 
compounds (Sigma), and quantification was based on the ratios of the peak areas of the compound to the standard. 
 
Animal ethics 
All BALB/c nude mice were purchased from the Chinese University of Hong Kong and maintained under pathogen-free 
conditions in the City University of Hong Kong. The studies involving animal all in accordance with the protocol and was 
approved by the Institutional Animal Ethics Committee. 
 
Statistical analysis 
All the results were expressed as Mean ± SD where applicable. GraphPad Prism 6 software (GraphPad Software) was 
used for statistical analysis. All the results are expressed as Mean ± SD. 
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Results 
 
Figure S1. TEM images of A) LDH; B) Pt(IV)/LDH; C) IDOi/LDH; D) Pt(IV)-IDOi(10:1)/LDH; E) Pt(IV)-IDOi(1:2)/LDH; F) Pt(IV)-
IDOi(1:10)/LDH; G) Pt(IV)-IDOi(1:40)/LDH; H) Pt(IV)-IDOi/LDH (1:245). 
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Figure S2. Western blot of IDO expression level with/without hIFN-γ stimulation. MCF-7, HeLa, A2780, A549, A549cisR, 
WI-38, MRC-5, and HCvEpC cells were seeded in 10 cm dish with/without hIFN-γ for 3 days, then the cells were collected 
for western blot. 
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Figure S3. Cellular accumulation of Pt in HeLa cells. The Pt concentration in each sample is 5 μM in A) and 10 μM.in 
B). HeLa cells were treated with cisplatin, cisplatin + IDOi (1:40), Pt(IV)/LDH and Pt(IV)-IDOi(1:40)/LDH for 8 h. Mean ± 
SD. 
To evaluate the efficient delivery and activation of Pt in HeLa cells, Pt accumulation in cells was assessed by ICP-OES. 
HeLa cells treated with cisplatin or cisplatin together with IDOi have similar intracellular levels of Pt (Figure S3). 
Pt(IV)/LDH and Pt(IV)-IDOi(1:40)/LDH ([Pt] = 5 μM) show significantly elevated levels of Pt compared with the small-
molecule itself, and the levels are 71.5 ± 5.3 and 443.7 ± 97.3 ng per 106 cells, respectively, suggesting the efficient 
delivery of Pt by the nanoparticles. We also measured the Pt level in the genomic DNA of the treated HeLa cells. A 15-
fold increase in genomic DNA is observed for Pt(IV)-IDOi(1:40)/LDH compared with cisplatin (Figure S4). These data 
clearly indicate the effective entrance of the Pt(IV) prodrug in Pt(IV)-IDOi/LDH into cancer cells and the efficient activation 
of the prodrug for damaging genomic DNA. 
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Figure S4. Pt levels of genomic DNA in total HeLa cells. The Pt concentration in each sample is 5 μM in A) and 10 μM.in 
B). HeLa cells were treated with cisplatin, cisplatin + IDOi (1:40), Pt(IV)/LDH, and Pt(IV)-IDOi(1:40)/LDH for 8 h. Mean 
± SD. 
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Figure S5. Inhibitory effect of A) D-1MT, B) IDOi, C) IDOi/LDH, D) Pt(IV)-IDOi(1:40)/LDH, and E) cisplatin + IDOi (1:40) 
on the level of kynurenine in HeLa cells after 48 h treatment containing hIFN-γ (25 ng/mL). The concentrations of 
complexes were added as indicated. Kynurenine concentrations were calculated using a F) kynurenine standard curve. 
Mean ± SD. 
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Figure S6. The apoptotic levels of HeLa cells in the HeLa/MLRs system tested by TUNEL assay. The concentration of 
Pt in the treatment is 5 µM. After 3 days incubation, all the samples were analyzed by a fluorescence microscope. Double 
staining samples of TUNEL (green) and PI (red) were viewed at 520 and 620 nm, respectively. All scale bars are 200 
μm. 
 
 
 
S15 
 
 
Figure S7. The apoptotic index (%) of HeLa cells in HeLa/MLRs. For the quantification of TUNEL assay, the apoptotic 
index was expressed as the percentage of TUNEL-positive cells out of the total number of cells counted. The treatment 
conditions for HeLa cells were: untreated, Pt(IV)-IDOi(1:40)/LDH ([Pt] = 5 μM), and Pt(IV)-IDOi(1:40)/LDH ([Pt] = 5 μM) 
+ PBMCs for 3 days of culture. * p < 0.05. Mean ± SD. 
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Figure S8. Cell viability (%) of PBMCs determined by MTS assay. The PBMCs were treated with Pt(IV)-IDOi(1:40)/LDH 
for 72 h in and without the presence of HeLa cells. Mean ± SD. 
The possibility of unintended or off-target effects of the nanohybrid was further investigated in the co-culture system. 
Cell viability of PBMCs was first tested in different treatment conditions using an MTS assay (Figure S8). The cell 
viabilities of PBMCs do not significantly change after exposure to the nanohybrid ([Pt] = 1 or 5 μM) for 3 days in and 
without the presence of HeLa cells, indicating that our nanohybrid hardly affects the viability of T cells, the major 
component of PBMCs.[7] Distributions of the nanohybrid in HeLa cells and PBMCs were quantified (Figures S9 - S10). 
After treatment for 72 h ([Pt] = 5 μM), the percentage of Pt in HeLa cells, PBMCs, and supernatant is 27.0%, 4.6%, and 
68.4%, respectively (Figure S9A), indicating that the nanohybrid is able to efficiently deliver Pt into HeLa cells rather 
than PBMCs.  
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Figure S9. Delivery efficiency (%) of Pt(IV)-IDOi(1:40)/LDH under 3 different treatment conditions for 72 h: A) HeLa + 
PBMCs + nanohybrid ([Pt] = 5 μM); B) HeLa + nanohybrid ([Pt] = 5 μM); and C) PBMCs + nanohybrid ([Pt] = 5 μM). The 
data was tested by ICP-MS to quantify the Pt level in HeLa cells, supernatant, and/or PBMCs. Nanohybrid is Pt(IV)-
IDOi(1:40)/LDH. Mean ± SD. 
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Figure S10. Cellular accumulation of Pt in PBMCs and T cells. The PBMCs in HeLa/MLRs system were treated with 
Pt(IV)-IDOi/LDH ([Pt] = 5 μM) for 3 days. After incubation, the PBMCs in each sample were harvested for cellular Pt 
accumulation test. The T cells were tested after cell sorting and quantified the Pt levels in the same way. Mean ± SD. 
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Figure S11. TEM images of nanoparticles incubated with blood plasma. Centrifuged nanoparticles were dispersed in fresh mice 
blood plasma. After vortex for 5 s, the TEM images were recorded for the mixture of blood plasma with A) LDH; B) Pt(IV)/LDH; C) 
IDOi/LDH; D) Pt(IV)-IDOi(1:40)/LDH. The rest of the samples was maintained in 37 ˚C for 24 h. TEM images were then achieved 
for the mixture of blood plasma with E) LDH; F) Pt(IV)/LDH; G) IDOi/LDH; H) Pt(IV)-IDOi(1:40)/LDH. 
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Figure S12. TEM images of BSA-coated nanoparticles in PBS or incubated with blood plasma. A) BSA-coated Pt(IV)-
IDOi(1:40)/LDH in PBS, B) BSA-coated Pt(IV)-IDOi(1:40)/LDH incubated with blood plasma and monitored at 0 h, and 
C) BSA-coated Pt(IV)-IDOi(1:40)/LDH incubated with blood plasma at 37 ºC and observed at 24 h. 
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Figure S13. The schedule of in vivo experiment to evaluate the immune-chemotherapeutic nanohybrid. HeLa cervical 
cancer cells (5 × 105 cell / 0.1 mL / mouse) were subcutaneously implanted in BALB/c nude mice at Day -7 to establish 
the xenograft mouse model (n = 5). When the tumor masses achieved a diameter of 5 - 8 mm, PBMCs (5 x 106 cell / 0.1 
mL / mouse) were intravenously injected, then BSA-coated Pt(IV)-IDOi(1:40)/LDH ([Pt] = 0.5 mg/kg) was injected and 
PBS was set as a negative control. The tumor dimension and body weight were measured every two days for total 14 
days of duration. 
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Figure S14. The change of body weight in 14 days after various treatment indicated. The PBMCs (5 x 106 cells/mouse) 
were injected intravenously at Day 0. BSA-coated Pt(IV)-IDOi(1:40)/LDH ([Pt] = 0.5 mg/kg) was injected for total 4 
injection. The body weight of each group was measured every two days for 14 days of duration. Mean ± SD, n = 5. 
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Figure S15. Concentration of free kynurenine and tryptophan 
in tumor samples from in vivo experiment using HPLC. 
Concentrations of A) kynurenine, B) tryptophan, C) ratio of 
kynurenine / tryptophan were calculated by using D) 
kynurenine standard curve, and E) tryptophan standard curve. 
The UV detector in HPLC was set at 365 and 280 nm to 
measure kynurenine and tryptophan levels, respectively. *** p 
< 0.001. Mean ± SD, n = 5. 
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Table S1. Measured co-loading nanoparticles containing Pt(IV) and/or IDOi. 
Pt:IDOi 
Loaded Pt 
(μmol/mg) 
Loaded inhibitor 
(μmol/mg) 
- 0.15 0 
- 0 14.56 
10:1 0.25 0.03 
1:2 0.27 0.58 
1:10 0.21 1.76 
1:40 0.29 12.04 
1:245 0.06 14.21 
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Table S2. Diameter and zeta potential of nanoplatform containing Pt(IV) and/or IDOi. 
Sample 
Number hydrodynamic size 
(d. nm) 
Zeta potential 
(mV) 
LDH 73.8 ± 2.1 46.0 ± 8.9 
Pt(IV)/LDH 84.1 ± 10.1 41.6 ± 9.7 
IDOi/LDH 182.6 ± 5.1 28.4 ± 3.9 
Pt(IV)-IDOi(10:1)/LDH 117.2 ± 5.1 43.9 ± 11.1 
Pt(IV)-IDOi(1:2)/LDH 158.2 ± 18.9 41.6 ± 8.9 
Pt(IV)-IDOi(1:10)/LDH 176.9 ± 11.6 29.4 ± 5.4 
Pt(IV)-IDOi(1:40)/LDH 216.7 ± 30.8 25.1 ± 9.6 
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Table S3. EC50 of different complexes in inhibiting the produce of kynurenine in HeLa cells. Cells were incubated with 
complexes and hIFN-γ for 48 h. 
 
 
 
 
 
 
 
 
 
 
 
 
  
Complex EC50/μM 
D-1MT > 1000 
IDOi 163 ± 24 
IDO/LDH 4.0 ± 0.3 
Pt(IV)-IDOi(1:40)/LDH 1.9 ± 0.2 
Cisplatin + IDOi (1:40) 27.8 ± 0.1 
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Table S4. Diameter and zeta potential of nanoplatform containing Pt(IV) and/or IDOi after incubation with blood plasma 
at 0 h and 24 h (37 ºC). 
Sample 
Number hydrodynamic size (d. nm)  Zeta potential (mV) 
0 h 24 h (37 ºC)  0 h 24 h (37 ºC) 
LDH 357.0 ± 72.2 355.3 ± 23.0  -9.1 ± 5.1 -26.8 ± 1.7  
Pt(IV)/LDH 503.2 ± 18.6 516.1 ± 47.9  -2.2 ± 2.2 -24.3 ± 1.6 
IDOi/LDH 496.3 ± 59.5 497.0 ± 48.4  -32.4 ± 4.7 -23.4 ± 6.9 
Pt(IV)-IDOi(1:40)/LDH 515.2 ± 55.7 547.4 ± 36.5  -24.2 ± 7.8 -25.0 ± 5.1  
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Table S5. Diameter and zeta potential of BSA-coated Pt(IV)-IDOi(1:40)/LDH with/without incubation with blood plasma 
at 37 ºC. 
Sample 
Number hydrodynamic 
size (d. nm) 
Zeta potential 
(mV) 
BSA-coated Pt(IV)-IDOi(1:40)/LDH 261.2 ± 49.8 -0.196 ± 0.1 
BSA-coated Pt(IV)-IDOi(1:40)/LDH in blood plasma at 0 h  293.4 ± 18.3 -2.26 ± 0.6 
BSA-coated Pt(IV)-IDOi(1:40)/LDH in blood plasma at 24 h 324.8 ± 64.7 -3.1 ± 0.4  
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